Lemon S M, Bancroft W H
J Infect Dis. 1979 Nov;140(5):798-801. doi: 10.1093/infdis/140.5.798.
PLC/PRF/5 hepatoma cells continue to produce hepatitis B surface antigen (HBsAg) after greater than 80 passages in vitro, but they do not express other markers of heaptitis B virus (HBV) replication. In this respect, they resemble most liver cells that are persistently infected with HBV. PLC/PRF/5 cells were cultured in the presence of adenine arabinoside, human fibroblast interferon, and ribavirin to determine whether production of HBsAg was sensitive to these antiviral agents. HBsAg released into culture media was detected by radioimmunoassay, and cellular protein synthesis was assessed by [3H]amino acid incorporation studies. A dose-related inhibition of HBsAg occurred with each antiviral agent that was tested, but in each case, this inhibition was matched by a reduction of cellular protein synthesis to a similar degree. Thus, no specific effect on the production of HBsAg was found with any of the antiviral agents tested.
PLC/PRF/5肝癌细胞在体外传代80次以上后仍继续产生乙型肝炎表面抗原(HBsAg),但它们不表达乙型肝炎病毒(HBV)复制的其他标志物。在这方面,它们类似于大多数持续感染HBV的肝细胞。将PLC/PRF/5细胞在阿糖腺苷、人成纤维细胞干扰素和利巴韦林存在的情况下进行培养,以确定HBsAg的产生是否对这些抗病毒药物敏感。通过放射免疫测定法检测释放到培养基中的HBsAg,并通过[3H]氨基酸掺入研究评估细胞蛋白质合成。所测试的每种抗病毒药物都出现了与剂量相关的HBsAg抑制,但在每种情况下,这种抑制都伴随着细胞蛋白质合成以相似程度的减少。因此,在所测试的任何抗病毒药物中均未发现对HBsAg产生的特异性影响。